GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » E10

NKTR (Nektar Therapeutics) E10 : $-19.51 (As of Mar. 2025)


View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Nektar Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2025 was $-3.600. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-19.51 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average E10 Growth Rate was -3.30% per year. During the past 5 years, the average E10 Growth Rate was -11.30% per year. During the past 10 years, the average E10 Growth Rate was -2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Nektar Therapeutics was 16.90% per year. The lowest was -25.70% per year. And the median was 3.70% per year.

As of today (2025-07-03), Nektar Therapeutics's current stock price is $25.53. Nektar Therapeutics's E10 for the quarter that ended in Mar. 2025 was $-19.51. Nektar Therapeutics's Shiller PE Ratio of today is .


Nektar Therapeutics E10 Historical Data

The historical data trend for Nektar Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics E10 Chart

Nektar Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.56 -16.70 -17.85 -17.90 -18.39

Nektar Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.77 -17.74 -19.13 -18.39 -19.51

Competitive Comparison of Nektar Therapeutics's E10

For the Biotechnology subindustry, Nektar Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Shiller PE Ratio falls into.


;
;

Nektar Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nektar Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-3.6/134.9266*134.9266
=-3.600

Current CPI (Mar. 2025) = 134.9266.

Nektar Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201506 -6.000 100.684 -8.041
201509 -0.900 100.392 -1.210
201512 -6.000 99.792 -8.112
201603 -2.100 100.470 -2.820
201606 -5.400 101.688 -7.165
201609 -4.800 101.861 -6.358
201612 -4.200 101.863 -5.563
201703 -6.300 102.862 -8.264
201706 -5.850 103.349 -7.637
201709 5.550 104.136 7.191
201712 -3.150 104.011 -4.086
201803 -9.000 105.290 -11.533
201806 79.950 106.317 101.465
201809 -8.400 106.507 -10.641
201812 -8.550 105.998 -10.883
201903 -10.350 107.251 -13.021
201906 -9.450 108.070 -11.798
201909 -8.400 108.329 -10.462
201912 -9.600 108.420 -11.947
202003 -11.700 108.902 -14.496
202006 -6.750 108.767 -8.373
202009 -9.150 109.815 -11.242
202012 -9.750 109.897 -11.971
202103 -10.200 111.754 -12.315
202106 -10.350 114.631 -12.182
202109 -10.500 115.734 -12.241
202112 -11.850 117.630 -13.593
202203 -7.350 121.301 -8.176
202206 -12.750 125.017 -13.761
202209 -4.650 125.227 -5.010
202212 -4.800 125.222 -5.172
202303 -10.950 127.348 -11.602
202306 -4.050 128.729 -4.245
202309 -3.600 129.860 -3.740
202312 -3.300 129.419 -3.440
202403 -2.850 131.776 -2.918
202406 -3.750 132.554 -3.817
202409 -2.700 133.029 -2.739
202412 0.450 133.157 0.456
202503 -3.600 134.927 -3.600

Add all the adjusted EPS together and divide 10 will get our e10.


Nektar Therapeutics  (NAS:NKTR) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Nektar Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics Business Description

Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Executives
Howard W Robin director, officer: President & CEO
Jonathan Zalevsky officer: Chief R&D Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Mark Andrew Wilson officer: SVP & General Counsel 1613 RAY DRIVE, BURLINGAME CA 94010
Robert Chess director, officer: Executive Chairman
Myriam Curet director 1020 KIFER ROAD, SUNNYVALE CA 94086
Jeffrey Robert Ajer director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Sandra A. Gardiner officer: Chief Financial Officer CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jillian B. Thomsen officer: VP & Chief Accounting Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Gil M Labrucherie officer: SVP, COO & CFO 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
John Northcott officer: SVP & Chief Commercial Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Diana Brainard director C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
R Scott Greer director 6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253
Lutz Lingnau director 15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945
Stephen K Doberstein officer: Chief Scientific Officer 129 ELSIE STREET, SAN FRANCISCO CA 94110